A Phase 1/1b, Open-label Clinical Study of Intratumoral/Intralesional Administration of MK-4621/JetPEI as Monotherapy or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 01 Sep 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; RGT 100 (Primary) ; RGT 100 (Primary) ; RGT 100 (Primary)
Indications Liver metastases; Solid tumours
Focus Adverse reactions
Sponsors Merck Sharp & Dohme

Most Recent Events

26 Feb 2019 Planned primary completion date changed from 14 Jan 2021 to 15 Apr 2021.
10 Jan 2019 Status changed from not yet recruiting to recruiting.
06 Dec 2018 Planned initiation date changed from 7 Dec 2018 to 17 Dec 2018.

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Welcome to AdisInsight